Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221318 | 0.99 | HRH3 (0.52) | HRH3ALDH1A1MAPTUSP2ALOX12 | |
| SCHEMBL5223521 | 0.97 | HRH3 (0.49) | HRH3ALDH1A1MAPTUSP2ALOX12 | |
| SCHEMBL5958480 | 0.86 | MAPT (0.63) | ALDH1A1MAPTUSP2KDM2BLMNA | |
| SCHEMBL5219025 | 0.86 | HRH3 (0.52) | HRH3ALDH1A1MAPTKDM2BLMNA | |
| SCHEMBL5218106 | 0.86 | HRH3 (0.58) | HRH3ALDH1A1KDM2BKMT2APOLB | |
| SCHEMBL5215698 | 0.86 | HRH3 (0.58) | HRH3ALDH1A1KDM2BKMT2APOLB | |
| SCHEMBL5223808 | 0.85 | ALDH1A1 (0.45) | HRH3ALDH1A1MAPTUSP2ALOX12 | |
| SCHEMBL5958398 | 0.85 | HRH3 (0.54) | HRH3ALDH1A1MAPTKDM2BTP53 | |
| SCHEMBL5217326 | 0.85 | MAPT (0.61) | ALDH1A1MAPTUSP2KDM2BLMNA | |
| SCHEMBL5220021 | 0.85 | HRH3 (0.59) | HRH3KDM2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474419-B1 | AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES | NOVO NORDISK AS (DK) | 2007-09-05 | — | — | EP | disclosed |
| US-7101898-B2 | For therapy of allergic rhinitis, ulcer or anorexia, diabetes, Alzheimer's disease, narcolepsy or attention deficit disorder | NOVO NORDISK A/S (DK) | 2006-09-05 | — | — | US | disclosed |
| EP-1474419-A1 | AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20030195190-A1 | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes | HIGH POINT PHARMACEUTICALS, LLC | 2003-10-16 | — | — | US | disclosed |
| WO-2003064411-A1 | AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES | NOVO NORDISK A/S (DK) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195190-A1 | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes | HRH3, HRH2, HRH4 | HRH3 1/4885ALDH1A1 2049/4885MAPT 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.